Actionable news
All posts from Actionable news
Actionable news in TSRO: TESARO, Inc.,

Janssen Biotech secures rights to PARP inhibitor for prostate cancer from TESARO

Johnson & Johnson's (NYSE:JNJ) Janssen Biotech inks a license and collaboration deal with TESARO (NASDAQ:TSRO) for exclusive global rights, except Japan, to develop and commercialize poly polymerase (PARP) inhibitor niraparib for the treatment of prostate cancer.

Under the terms of the...